Hypogonadism and effects on quality of life in previously treated germ cell tumor survivors: A single-centre, non-randomized, prospective observational study.

10079 Background: Prior studies have shown that around 12% to 16% Germ Cell Tumour (GCT) survivors can have subnormal serum testosterone level as well as up to 15% reported decreased health related Quality of life (QOL). It is important to identify the correlation of hypogonadism with QOL scores in survivors of GCT. Methods: This is a single-centre, non-randomized, prospective observational study in GCT survivors 18-50 yrs of age previously treated with Surgery and Chemotherapy or Surgery alone. Total testosterone was measured at baseline, 3, and 6 months. Patients completed a validated QOL questionnaire at baseline, 3, and 6 months. Patients could get supplemental testosterone as standard of care. Mean QOL scores were compared between two treatment groups and within each group between survivors with hypogonadism (serum testosterone level < 300 ng/dL) versus without ( > 300 ng/dL). A two-sided independent-groups t test was used to compare means. Results: We evaluated 199 GCT survivors. At baseline, the prevalence of hypogonadism was 48.2% overall, 51.45% in Chemo + Surgery group (C) and 44.7 % in surgery alone (CN) (p = 0.39). Overall, there was no statistically significant difference in QOL scores between two groups, except the C group exhibited greater Aging Male Symptoms (AMS) on the AMS scale score than the CN group, at baseline and 6 months. However, compared to patients with testosterone ≥ 300, patients with hypogonadism reported more fatigue (p = .04), poor sleep quality (p = .02) and worse general health (p = .006) at baseline. There was no statistically significant difference in depression (p = .33), or sexual functioning (satisfaction, p = .44; interest, p = .56; ability to have an erection, p = .23). There were no statistical differences in QOL between testosterone groups at 3 months or 6 months; however, sample sizes were small for participants who were measured on the testosterone at 3 months and 6 months. Conclusions: GCT survivors treated with chemo exhibited greater Aging Male Symptoms compared to chemo naive group. Hypogonadism was associated with sleep disturbance, worse energy and lower general health QOL scores at baseline.